Howard G. Birnbaum, PhD

Articles by Howard G. Birnbaum, PhD

Drivers of Excess Costs of Opioid Abuse Among a Commercially Insured Population

ByLauren M. Scarpati, PhD,Noam Y. Kirson, PhD,Miriam L. Zichlin, MPH,Zitong B. Jia, BA,Howard G. Birnbaum, PhD,Jaren C. Howard, PharmD

May 22nd 2017

The healthcare burden of opioid abuse is substantial; abusers often have complex healthcare needs and may require care beyond that which is required to treat abuse.

Cost of Post-Traumatic Stress Disorder vs Major Depressive Disorder Among Patients Covered by Medicaid or Private Insurance

ByJasmina I. Ivanova, MA,Howard G. Birnbaum, PhD,Lei Chen, MD, MS,Amy M. Duhig, PhD,Elias J. Dayoub, BA,Evan S. Kantor, BS,Matthew B. Schiller, BA,Glenn A. Phillips, PhD

August 9th 2011

Post-traumatic stress disorder was associated with 4.2% to 9.3% higher annual per-patient healthcare costs compared with MDD among patients covered by Medicaid or private insurance.

Analytic Models to Identify Patients at Risk for Prescription Opioid Abuse

ByAlan G. White, PhD,Howard G. Birnbaum, PhD,Matt Schiller, BA,Jackson Tang, BSc,Nathaniel P. Katz, MD

December 7th 2009

This study evaluates the feasibility of using claims data to evaluate risk factors for prescription opioid abuse among patients in a privately insured population.

Adherence to Inhaled Corticosteroid Use and Local Adverse Events in Persistent Asthma

ByJasmina I. Ivanova, MA,Howard G. Birnbaum, PhD,Matthew Hsieh, BA,Andrew P. Yu, PhD,Brian Seal, PhD,Thys van der Molen, PhD,Srinivas Emani, PhD,Richard A. Rosiello, MD,Gene L. Colice, MD

December 1st 2008

This study evaluated the association between patient-reported and medical record–abstracted local adverse events and patient-reported and claims-based adherence to inhaled corticosteroid therapy.